In Vitro Diagnostics (IVD) Market Size, Share & Trends Analysis Report By Product, By Application, By Technology (Clinical Chemistry, Molecular Diagnostics, Coagulation, Microbiology), By End User, And Segment Forecasts, 2013 - 2022

  • ID: 4582041
  • Report
  • 129 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Leica Biosystems
  • Roche Diagnostics
  • MORE
The global in vitro diagnostics (IVD) market size is expected to reach USD 97.01 billion by 2022, rising at a CAGR of 6.8% during the forecast period. Increasing incidence of sexually transmitted and gastrointestinal diseases coupled with surging demand for large-scale screening, particularly for cancer, is stimulating the growth of the market. IVD helps in detecting whether a particular medicine or treatment would work on a patient.

Constant innovations and advancements play a pivotal role in the development of the market. IVD is being increasingly used in every stage of the patient care and nearly each healthcare setting. Though, most of these tests are remotely performed, making their presence unnoticed.

Various organizations are functioning to monitor the market. For instance, BIVDA is an association of companies with high involvement and interest and represents manufacturers and distributors functioning in the U.K.

Rapidly changing healthcare environment and growing acknowledgment of diagnostics role in patient care, along with rising awareness regarding importance of early diagnosis of chronic diseases, are likely to boost the growth of the IVD market.

Surging demand for point-of-care detection and identification of various infectious diseases such respiratory tract infections, including Legionnaires’ disease, RSV, influenza, and pneumonia, coupled with pathogens causing filariasis and malaria, is providing a significant push to the market.

Further key findings from the report suggest:
  • Reagents were the largest segment in 2016 and are expected to show the fastest growth over the forecast period owing to rising R&D activities pertaining to self-test and point-of-care products
  • Infectious disease dominated the market in 2016 due to increasing incidence of infectious diseases such as pneumonia, tuberculosis, and HIV.
  • Hospitals were one of the largest segment in 2016 owing to rising number of hospitalized patients
  • North America dominated the IVD market in 2016 due to rising prevalence of chronic disorders such as respiratory diseases and cancer in this region
  • Asia Pacific is expected to be the fastest growing region over the forecast period. Rising per capita healthcare expenditure, government initiatives, and growing clinical research activities for advanced diagnostics are likely to drive the regional market.
This report will be delivered in five days upon ordering.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Abbott Laboratories
  • Beckman Coulter Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Leica Biosystems
  • Roche Diagnostics
  • MORE
Chapter 1. Executive Summary
1.1. IVD - Industry Summary and Critical Success Factors (CSFs)

Chapter 2. IVD Industry Outlook
2.1. Market Segmentation
2.2. Market Size and Growth Prospects
2.3. IVD Market Dynamics
2.4. Key Opportunities Prioritized
2.5. Industry Analysis - Porter's
2.6. Molecular Diagnostics - Company Market Share Analysis
2.7. Tissue Diagnostics - Company Market Share Analysis
2.8. Professional Diagnostics - Company Market Share Analysis
2.9. Diabetes Monitoring - Company Market Share Analysis
2.10. IVD Market PESTEL Analysis, 2012

Chapter 3. IVD Product Outlook
3.1. Molecular Diagnostics
3.2. Tissue Diagnostics
3.3. Diabetes Monitoring
3.4. Professional Diagnostics

Chapter 4. IVD Regional Outlook
4.1. North America
4.2. Europe
4.3. Asia-Pacific
4.4. RoW

Chapter 5. Competitive Landscape
5.1 Abbott Laboratories
5.1.1 Company Overview
5.1.2 Financial Performance
5.1.3 Product Benchmarking
5.1.4 Strategic Initiatives
5.2 Roche Diagnostics
5.2.1 Company Overview
5.2.2 Financial Performance
5.2.3 Product Benchmarking
5.2.4 Strategic Initiatives
5.3 Siemens Healthcare
5.3.1 Company Overview
5.3.2 Financial Performance
5.3.3 Product Benchmarking
5.3.4 Strategic Initiatives
5.4 Johnson and Johnson
5.4.1 Company Overview
5.4.2 Financial Performance
5.4.3 Product Benchmarking
5.4.4 Strategic Initiatives
5.5 Bio-Rad Laboratories
5.5.1 Company Overview
5.5.2 Financial Performance
5.5.3 Product Benchmarking
5.5.4 Strategic Initiatives
5.6 Beckman Coulter Inc.
5.6.1 Company Overview
5.6.2 Financial Performance
5.6.3 Product Benchmarking
5.6.4 Strategic Initiatives
5.7 Becton Dickinson
5.7.1 Company Overview
5.7.2 Financial Performance
5.7.3 Product Benchmarking
5.7.4 Strategic Initiatives
5.8 bioMerieux
5.8.1 Company Overview
5.8.2 Financial Performance
5.8.3 Product Benchmarking
5.8.4 Strategic Initiatives
5.9 Sysmex
5.9.1 Company Overview
5.9.2 Financial Performance
5.9.3 Product Benchmarking
5.9.4 Strategic Initiatives
5.10 Bayer Healthcare
5.10.1 Company Overview
5.10.2 Financial Performance
5.10.3 Product Benchmarking
5.10.4 Strategic Initiatives
5.11 Alere Inc.
5.11 .1 Company Overview
5.11.2 Financial Performance
5.11.3 Product Benchmarking
5.11.4 Strategic Initiatives
5.12 Danaher Corporation
5.12.1 Company Overview
5.12.2 Financial Performance
5.12.3 Product Benchmarking
5.12.4 Strategic Initiatives
5.13 Hologic (Gen-Probe)
5.13.1 Company Overview
5.13.2 Financial Performance
5.13.3 Product Benchmarking
5.13.4 Strategic Initiatives
5.14 Novartis
5.14.1 Company Overview
5.14.2 Financial Performance
5.14.3 Product Benchmarking
5.14.4 Strategic Initiatives
5.15 Cepheid
5.15.1 Company Overview
5.15.2 Financial Performance
5.15.3 Product Benchmarking
5.15.4 Strategic Initiatives
5.16 Qiagen
5.16.1 Company Overview
5.16.2 Financial Performance
5.16.3 Product Benchmarking
5.16.4 Strategic Initiatives
5.17 Leica Biosystems
5.17.1 Company Overview
5.17.2 Financial Performance
5.17.3 Product Benchmarking
5.17.4 Strategic Initiatives
5.18 Dako
5.18.1 Company Overview
5.18.2 Financial Performance
5.18.3 Product Benchmarking
5.18.4 Strategic Initiatives

Chapter 6. Methodology and Scope
6.1. Research Methodology
6.2. Research Scope & Assumption
6.3. List of Data Sources

List of Tables
1. IVD - Industry Summary & Critical Success Factors (CSFs)
2. Global IVD Revenue, 2012 - 2020 (USD million)
3. Global IVD Market Revenue by Region, 2012 - 2020 (USD million)
4. Global IVD Market Revenue by Products, 2012 - 2020 (USD million)
5. Global Tissue Diagnostics Demand, 2012 to 2020 (USD million)
6. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
7. Global Molecular Diagnostics Demand, 2012 to 2020 (USD million)
8. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
9. Global Professional Diagnostics Demand, 2012 to 2020 (USD million)
10. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
11. Global Diabetes Monitoring Demand, 2012 to 2020 (USD million)
12. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
13. North America IVD demand, by Products, 2012 - 2020 (USD million)
14. Europe IVD demand, by Products, 2012 - 2020 (USD million)
15. Asia Pacific IVD demand, by Products, 2012 - 2020 (USD million)
16. RoW IVD demand, by Products, 2012 - 2020 (USD million)

List of Figures
1. IVD Market Segmentation
2. Global IVD Market Revenue, 2012 - 2020
3. IVD Market Dynamics
4. Global population base over the age group of 60 years, 2010 and 2017 (million)
5. Global diabetes prevalence, 2010 and 2017 (million)
6. Molecular Diagnostics Company Market Share Analysis, 2012
7. Tissue Diagnostics Company Market Share Analysis, 2012
8. Professional Diagnostics Company Market Share Analysis, 2012
9. Diabetes Monitoring Company Market Share Analysis, 2012
10. Key Opportunities Prioritized
11. Industry Analysis - Porter's
12. IVD PESTEL Analysis, 2012
13. Global IVD Revenue, by Products, 2012 & 2020
14. Global Molecular Diagnostics Demand, by Region, 2012 to 2020 (USD million)
15. Global Tissue Diagnostics Demand, by Region, 2012 to 2020 (USD million)
16. Global Professional Diagnostics Demand, by Region, 2012 to 2020 (USD million)
17. Global Diabetes Monitoring Demand, by Region, 2012 to 2020 (USD million)
18. North America IVD Demand, by Products, 2012 to 2020 (USD million)
19. Europe IVD Demand, by Products, 2012 to 2020 (USD million)
20. Asia Pacific IVD Demand, by Products, 2012 to 2020 (USD million)
21. RoW IVD Demand, by Products, 2012 to 2020 (USD million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Abbott Laboratories
  • Roche Diagnostics
  • Siemens Healthcare
  • Johnson and Johnson
  • Bio-Rad Laboratories
  • Beckman Coulter Inc.
  • Becton Dickinson
  • bioMerieux
  • Sysmex
  • Bayer Healthcare
  • Alere Inc.
  • Danaher Corporation
  • Hologic (Gen-Probe)
  • Novartis
  • Cepheid
  • Qiagen
  • Leica Biosystems
  • Dako
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll